Acquisitions (Schedule Of Revenue And Income And Net Loss Included In Consolidated Statements of Operations) (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		5 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Revenue		$ 884,335	$ 745,727		$ 2,768,761	$ 2,195,021
Net loss attributable to Endo International plc		$ (218,919)	$ (1,050,442)		$ (9,210)	$ (1,376,579)
Auxilium Pharmaceuticals, Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Revenue				$ 237,807
Net loss attributable to Endo International plc				$ (257,597)
Basic and diluted net loss per share (in dollars per share)				$ (1.37)
Par Pharmaceutical Holdings, Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Revenue	$ 23,413
Net loss attributable to Endo International plc	$ (17,441)
Basic and diluted net loss per share (in dollars per share)	$ (0.09)